Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature

被引：11
|
作者：
Tolcher, Anthony W.
Alley, Evan W.
Chichili, Guru
Baughman, Jan E.
Moore, Paul A.
Bonvini, Ezio
Vasselli, James Robert
Wigginton, Jon M.
Powderly, John D.
机构：
[1] START San Antonio, San Antonio, TX USA
[2] Univ Pennsylvania, Philadelphia, PA USA
[3] MacroGenics Inc, Rockville, MD USA
[4] MacroGenics Inc, Bethesda, MD USA
[5] MacroGenics Inc, Frederick, MD USA
[6] Carolina BioOncol Inst, Huntersville, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS3105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3105
引用
收藏
页数：2
相关论文
共 50 条
  • [41] B7-H3 (CD276) on circulating epithelial tumor cells (CETCs) correlates with proliferation marker Ki-67 and may be associated with aggressiveness of tumor in breast cancer patients
    Pizon, M.
    Schott, D.
    Pachmann, U.
    Pachmann, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection
    Scilla, Katherine A.
    Zandberg, Dan P.
    Bentzen, Soren M.
    Mainor, Candace
    Heath, Jonathon
    Ioffe, Olga B.
    Cellini, Ashley L.
    Edelman, Martin J.
    Riedel, David J.
    Feliciano, Josephine L.
    LUNG CANCER, 2018, 123 : 87 - 90
  • [43] Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
    Powderly, John D.
    Jang, Sekwon
    Lohr, Joanna
    Spira, Alexander, I
    Bohac, Gerry C.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors
    Cheng, Ying
    Lisberg, Aaron
    Lemech, Charlotte
    Abed, Afaf
    Chaudhry, Arvind
    Schmidt, Andrew
    Lu, Xin
    Zhu, Zhongyuan
    Gu, Wei
    Qiu, Yang
    Shi, Rong
    Zhang, Bin
    CANCER RESEARCH, 2024, 84 (07)
  • [45] DB-1419, a first-in-class bispecific ADC targeting B7-H3 and PD-L1 with a DNA topoisomerase I inhibitor, exhibits promising efficacy and safety in preclinical models
    Li, C.
    Yao, J.
    Yang, J.
    Li, Z.
    Shi, R.
    Qiu, Y.
    Hua, H.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S72 - S72
  • [46] FT573: Preclinical development of multiplexed-engineered iPSC-derived NK cells expressing a novel camelid nanobody chimeric antigen receptor (CAR) targeting pan-cancer antigen B7-H3
    Zorko, Nicholas
    Cichocki, Frank
    Goulding, John
    Hancock, Bryan
    Blum, Robert
    Pribadi, Mochtar
    Gaertner, Bjoern
    Lee, Tom
    Felices, Martin
    Bjordahl, Ryan
    Valamehr, Bahram
    Miller, Jeffrey S.
    CANCER RESEARCH, 2022, 82 (12)
  • [47] A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.
    Doi, Toshihiko
    Yamamoto, Noboru
    Kitano, Shigehisa
    Latek, Robert
    Hou, Jianrui
    Tanaka, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
    Jang, Sekwon
    Powderly, John D.
    Spira, Alexander I.
    Bakkacha, Ouiam
    Loo, Deryk
    Bohac, Gerry C.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] UPDATES ON BRAINCHILD-01,-02, AND-03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
    Vitanza, Nicholas
    Gust, Juliane
    Wilson, Ashley
    Huang, Wenjun
    Perez, Francisco
    Wright, Jason
    Leary, Sarah
    Cole, Bonnie
    Albert, Catherine
    Pinto, Navin
    Orentas, Rimas
    Jensen, Michael
    Park, Julie
    NEURO-ONCOLOGY, 2020, 22 : 360 - 360
  • [50] ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3-targeting antibody-drug conjugate, in patients with advanced solid tumor
    Wang, Jie
    Duan, Jianchun
    Xing, Ligang
    Sun, Yuping
    Guo, Wei
    Wang, Haiying
    Chen, Jianhua
    Han, Liang
    Liu, Baogang
    Wang, Qiming
    Hu, Ying
    Wei, Hongying
    Li, Chuan
    Huang, Qiqi
    Dong, Yiwei
    Wu, Qiong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345